These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29227467)

  • 41. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.
    Baxter R; Keshavan P; Welsch JA; Han L; Smolenov I
    Hum Vaccin Immunother; 2016 May; 12(5):1300-10. PubMed ID: 26829877
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serogroup C
    Findlow H; Campbell H; Lucidarme J; Andrews N; Linley E; Ladhani S; Borrow R
    Euro Surveill; 2019 Jan; 24(1):. PubMed ID: 30621818
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine.
    de Voer RM; Mollema L; Schepp RM; de Greeff SC; van Gageldonk PG; de Melker HE; Sanders EA; Berbers GA; van der Klis FR
    PLoS One; 2010 Aug; 5(8):e12144. PubMed ID: 20730091
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.
    Snape MD; Kelly DF; Lewis S; Banner C; Kibwana L; Moore CE; Diggle L; John T; Yu LM; Borrow R; Borkowski A; Nau C; Pollard AJ
    BMJ; 2008 Jun; 336(7659):1487-91. PubMed ID: 18535032
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
    de Whalley PC; Snape MD; Plested E; Thompson B; Nuthall E; Omar O; Borrow R; Pollard AJ
    Arch Dis Child; 2013 Sep; 98(9):686-91. PubMed ID: 23853000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine.
    Knuf M; Helm K; Kolhe D; Van Der Wielen M; Baine Y
    Vaccine; 2018 May; 36(23):3286-3295. PubMed ID: 29724511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
    Pace D; Snape M; Westcar S; Oluwalana C; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
    Arch Dis Child; 2008 Nov; 93(11):963-70. PubMed ID: 18463125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers.
    Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Stoney T; Heron L; Lambert S; Mesaros N; Peddiraju K; Miller JM
    Pediatr Infect Dis J; 2013 Feb; 32(2):169-74. PubMed ID: 23080288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis.
    Bettinger JA; Scheifele DW; Halperin SA; Kellner JD; Vanderkooi OG; Schryvers A; De Serres G; Alcantara J
    Vaccine; 2012 Jun; 30(27):4023-7. PubMed ID: 22537988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
    J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
    Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
    Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age.
    Snape MD; Voysey M; Finn A; Bona G; Esposito S; Principi N; Diez-Domingo J; Sokal E; Kieninger D; Prymula R; Dull PM; Kohl I; Barone M; Wang H; Toneatto D; Pollard AJ;
    Pediatr Infect Dis J; 2016 Apr; 35(4):e113-23. PubMed ID: 26756390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.
    Trotter CL; Borrow R; Findlow J; Holland A; Frankland S; Andrews NJ; Miller E
    Clin Vaccine Immunol; 2008 Nov; 15(11):1694-8. PubMed ID: 18827191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparison on the levels of human serum antibody against Neisseria meningitidis serogroup C measured using serum bactericidal assay and ELISA].
    Zhu BQ; Xu L; Zhou HJ; Shao ZJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 May; 33(5):521-4. PubMed ID: 22883183
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?
    Stoof SP; Buisman AM; van Rooijen DM; Boonacker R; van der Klis FR; Sanders EA; Berbers GA
    PLoS One; 2015; 10(10):e0138665. PubMed ID: 26458006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy.
    Neri A; Fabiani M; Barbui AM; Vocale C; Miglietta A; Fazio C; Carannante A; Palmieri A; Vacca P; Ambrosio L; Stefanelli P
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims.
    Memish ZA; Yezli S; Almasri M; Assiri A; Turkestani A; Findlow H; Bai X; Borrow R
    Int J Infect Dis; 2014 Nov; 28():171-5. PubMed ID: 25307887
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults.
    de Voer RM; van der Klis FR; Engels CW; Schepp RM; van de Kassteele J; Sanders EA; Rijkers GT; Berbers GA
    Vaccine; 2009 Nov; 27(50):6974-82. PubMed ID: 19800445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
    Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
    Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Update on the use of meningococcal serogroup C CRM₁₉₇-conjugate vaccine (Meningitec) against meningitis.
    Badahdah AM; Rashid H; Khatami A
    Expert Rev Vaccines; 2016; 15(1):9-29. PubMed ID: 26560735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.